Dr. Neelapu on ALLO-501 Plus ALLO-647 in Relapsed/Refractory B-Cell Lymphomas

Sattva Neelapu, MD, discusses the mechanism of action of ALLO-501 when paired with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Sattva Neelapu, MD, professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of ALLO-501 when paired with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma (LBCL) or follicular lymphoma.

ALLO-501 is an investigational, anti-CD19 allogeneic CAR T-cell therapy that disrupts the TCR alpha constant gene to reduce the risk of graft-versus-host disease, says Neelapu. Additionally, ALLO-501 disrupts the CD52 gene, which allows it to be paired with the anti-CD52 monoclonal antibody ALLO-647 to expand the donor T cells and improve their persistence in a patient, explains Neelapu.

At the 2020 ASCO Virtual Scientific Program, results from the first-in-human, phase 1 ALPHA study examining these agents in combination, found that ALLO-501 and ALLO-647 a manageable safety profile in patients with relapsed/refractory LBCL or follicular lymphoma. The former shows evidence of clinical activity in patients with advanced non-Hodgkin lymphoma and the latter may serve as an effective and selective lymphodepleting agent with CD52 gene editing.

Related Videos
Jeffery Zonder, MD
Julie Renee Brahmer, MD
Brian Mitzman, MD, FACS, FCCP
Bradley W. Christensen, MD
Anne Chiang, MD, PhD, associate professor, medical oncology, Yale School of Medicine, associate cancer center director, Clinical Initiatives, Smilow Cancer Hospital, Yale Cancer Center
Dario R. Roque, MD, assistant professor of Obstetrics and Gynecology (Gynecologic Oncology), Northwestern University’s Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern Medicine
Natalie S. Callander, MD
Brian Henick, MD
Abhinav Deol, MD
Veronika Bachanova, MD, PhD
Related Content